Compare ENVA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | MLYS |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | ENVA | MLYS |
|---|---|---|
| Price | $162.69 | $37.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $155.40 | $46.40 |
| AVG Volume (30 Days) | 234.5K | ★ 1.7M |
| Earning Date | 10-23-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.62 | N/A |
| EPS | ★ 10.82 | N/A |
| Revenue | ★ $1,414,115,000.00 | N/A |
| Revenue This Year | $159.72 | N/A |
| Revenue Next Year | $16.16 | N/A |
| P/E Ratio | $15.04 | ★ N/A |
| Revenue Growth | ★ 20.78 | N/A |
| 52 Week Low | $79.41 | $8.24 |
| 52 Week High | $164.42 | $47.65 |
| Indicator | ENVA | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 86.34 | 40.09 |
| Support Level | $134.00 | $35.77 |
| Resistance Level | $132.15 | $44.13 |
| Average True Range (ATR) | 4.32 | 1.93 |
| MACD | 2.90 | -0.64 |
| Stochastic Oscillator | 98.56 | 14.95 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.